Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation / 전남의대학술지
Chonnam Medical Journal
;
: 6-11, 2020.
Article
Dans Anglais
| WPRIM
| ID: wpr-787280
ABSTRACT
Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Nations Unies
/
Récepteurs aux antigènes
/
Lymphocytes T
/
Cause de décès
/
Association thérapeutique
/
Carcinogenèse
/
Thérapie cellulaire et tissulaire
/
Système immunitaire
/
Ligands
/
Réaction antigène-anticorps
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Chonnam Medical Journal
Année:
2020
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS